{"type":"trials","record":{"id":41805,"source_id":"clinicaltrials-gov","external_id":"NCT05893537","title":"Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).","brief_summary":"This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.","overall_status":"Terminated","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Cognition Therapeutics","enrollment":100,"countries":["United States"],"start_date":"2023-06-16","completion_date":"2025-03-28","last_update_date":"2025-04-16","source_url":"https://clinicaltrials.gov/study/NCT05893537","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"CT1812 200 mg; Placebo","organization":"Cognition Therapeutics","interventions":["Active Comparator CT1812","Placebo Comparator"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye. — Baseline through Week 104","Safety and Tolerability of CT1812 — Baseline through Week 104","Plasma concentration of CT1812 — Baseline through Week 104"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Active Comparator CT1812","Placebo Comparator"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05893537","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-06-16 to 2025-03-28","comparator":"CT1812 200 mg; Placebo","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.874Z","intervention":["Active Comparator CT1812","Placebo Comparator"],"participants":100,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye. — Baseline through Week 104","Safety and Tolerability of CT1812 — Baseline through Week 104","Plasma concentration of CT1812 — Baseline through Week 104"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41805","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}